SUPN Supernus Pharmaceuticals
- 30.270
- +0.190+0.63%
- 30.270
- 0.0000.00%
Supernus Pharmaceuticals News
Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $41
Supernus Pharmaceuticals Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals (SUPN) Receives a Buy From Piper Sandler
Supernus Pharmaceuticals (SUPN) Receives a Buy From Piper Sandler
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43
Supernus Pharmaceuticals Analyst Ratings
Promising Progress and Potential of Qelbree Bolsters Buy Rating for Supernus Pharmaceuticals
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42
Supernus Pharmaceuticals Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)
Piper Sandler Sticks to Their Buy Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $46 From $45, Keeps Overweight Rating
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Cue Biopharma (CUE) and Guardant Health (GH)
Jefferies Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Adjusts Supernus Pharmaceuticals Price Target to $47 From $40, Maintains Overweight Rating
Supernus Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
